2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Neoplasms
2
Myocardial Reperfusion Injury
2
Cardiotoxicity
2
Vomiting
1
Uveal Melanoma
1
Thrombosis
1
Substance Withdrawal Syndrome
1
Retinal Diseases
1
Reperfusion Injury
1
Pain, Postoperative
1
Opioid-Related Disorders
1
Nausea
1
Melanoma
1
Macular Degeneration
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Choroid Diseases
1
Breast Neoplasms
1
Interventions
Cisplatin
258
Radiotherapy
193
Cetuximab
151
pembrolizumab
123
Docetaxel
97
Fluorouracil
92
Carboplatin
80
Paclitaxel
78
Radiotherapy, Intensity-Modulated
72
Surveys and Questionnaires
46
Nivolumab
42
Drug Therapy
34
Radiation
33
Blood Specimen Collection
27
Erlotinib Hydrochloride
26
Gemcitabine
25
Immunohistochemistry
22
Gefitinib
22
Cyclophosphamide
22
Surgical Procedures, Operative
21
Standard of Care
20
durvalumab
19
Pemetrexed
19
Magnetic Resonance Spectroscopy
19
Radiosurgery
17
Capecitabine
17
Chemotherapy, Adjuvant
16
Celecoxib
16
Biopsy
16
atezolizumab
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
salicylhydroxamic acid
×
Clear all
NCT02548377
2018-03-05
RIPC-HNC
Aarhus University Hospital Skejby
Phase NA
Completed
60 enrolled